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STUDY PROTOCOL Open Access
Laser peripheral iridotomy versus laser
peripheral iridotomy plus laser peripheral
iridoplasty in the treatment of multi-
mechanism angle closure: study protocol
for a randomized controlled trial
Shida Chen1, Jianhua Lv2, Sujie Fan3, Hong Zhang4, Lin Xie5, Ling Xu6, Bing Jiang7, Huipin Yuan8, Yuanbo Liang9,
Shuning Li10, Pingyan Chen11, Xiulan Zhang1*, Ningli Wang10* and for the Multi-mechanism Angle Closure Study
(MACs) group
Abstract
Background: China has the largest burden of primary angle-closure glaucoma (PACG) worldwide. The mechanism of the
angle closure is complex and includes pupillary block and non-pupillary block. Currently, opinion is that laser peripheral
iridotomy (LPI) alone is not sufficient to prevent disease progression. Laser peripheral iridoplasty (LPIP) is an alternative and
effective way of widening the angle recess in eyes that are affected by primary angle closure (PAC). However, it is not
known if greater benefit would be achieved using LPI plus LPIP for PAC with multiple mechanisms (MAC). Thus, the aim of
this study is to demonstrate if LPI plus LPIP would be more effective than single LPI in controlling the progression of PAC
with multiple mechanisms, based on ultrasound biomicroscopy (UBM) classification. A secondary aim is to determine
whether or not this would result in the use of less medication and/or prolong the time to antiglaucoma surgery.
Methods: This multiple-mechanism angle-closure study will comprise a 3-year, multicenter, randomized, parallel-group,
open-label, superiority trial, the aim of which will be to evaluate the safety and efficacy of LPI plus LPIP versus LPI for PAC.
It is anticipated that 240 adults, diagnosed with PAC (the mechanism of angle closure will be assessed by UBM and it will
be determined whether or not it involves multiple mechanisms) will be recruited from ten ophthalmic centers in China.
Participants will be randomly allocated to receive either single LPI or LPI plus LPIP. Participant assessment will be designed
to test the rate of disease progression and who will be followed up for 3 years. The primary outcome will be the disease
progression rate and a comparison will be made between the LPI and LPI plus LPIP groups using Pearson’s χ2 test.
Logistic regression analysis will be performed to account for the central effect.
(Continued on next page)
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Discussion: If the LPI plus LPIP is found to significantly decrease the rate of PAC progression, this intervention could
potentially be a standard therapy to be used to treat PAC when multiple mechanisms are involved in angle closure.
Subsequently, this would have the potential to delay the rate of PAC progression to PACG and delay the time to the
administration of antiglaucoma medication or trabeculectomy surgery.
Trial registration: ClinicalTrials.gov, NCT02613013. Registered on 24 November 2015.
In fact, the study was due to start in late October 2015, however, there were no patients recruited in October, and when
we registered at ClinicalTrials.gov on 5 November 2015, we received suggestions on the English translation of our
protocol from the PRS Team at Clinicaltrial.gov, so the final successful registration date was on 24 November 2015.
Keywords: PAC, PACG, Primary angle closure, Laser peripheral iridoplasty, Laser peripheral iridotomy, LPI, LPIP, Primary
angle-closure glaucoma
Background
Glaucoma is the second leading cause of irreversible
blindness and it is estimated that there will be 79.6 mil-
lion glaucoma patients globally by 2020. Although angle-
closure glaucoma (ACG) only accounts for 26% of all
glaucoma, it is expected that angle-closure glaucoma will
affect 87% of Asian glaucoma patients, with bilateral
blindness recorded in 5.9 million people with ACG [1].
It was found in a population-based study that China has
the largest burden of primary angle-closure glaucoma
(PACG) in the world [2].
Laser peripheral iridotomy (LPI) is the suggested ini-
tial treatment for primary angle closure (PAC) and early
PACG as it eliminates pupillary block, allowing the con-
vex iris to flatten, while widening the anterior chamber
angle [3]. However, the pathophysiological features that
underlie PAC are complex and include pupillary block
and non-pupillary block mechanisms [4].
It was found in our previous ultrasound biomicroscopy
(UBM)-based study that multiple mechanisms of angle
closure were found in approximately 55% of PACG pa-
tients. The causes of the angle closure include pupillary
block leading to peripheral iris bombe, anterior rotation of
the ciliary body, and a thickened and anteriorly located
peripheral iris [5]. Therefore, LPI alone may not be effect-
ive in angle closure caused by multiple mechanisms.
It was discovered in the Liwan Eye Study and Zhongshan
Angle-Closure Prevention Trial that approximately 20% of
Chinese eyes with suspected PAC had residual angle clos-
ure after single iridotomy and the greater angle width fol-
lowing iridotomy further decreased as time went on [6, 7].
Choi et al. followed up eyes with peripheral anterior syne-
chia (PAS) after LPI for a mean of 34.4 months and found
that disease progressed in 32% of the eyes due to the exist-
ence of a non-pupillary block component in angle closure,
i.e., plateau iris [8]. It was shown in a 2-year follow-up study
on primary angle closure suspects (PACS) after LPI that
roughly 28% of the patients progressed to PAC. A decreas-
ing anterior chamber area was predictive of progression
from PACS to PAC [9].
Contraction burns to the peripheral iris result from
peripheral iridolasty, leading to contraction of the per-
ipheral iris stroma and the creation of a space between
the anterior iris surface and the trabecular meshwork
[10]. It has also been suggested that this effectively
opens up the appositionally closed portions of the drain-
age angle, even resulting in a synechiolysis effect [11].
Ritch et al. found that laser peripheral iridoplasty (LPIP)
was highly efficient in eliminating residual appositional
closure following LPI caused by plateau iris [12].
Therefore, it is reasonable to hypothesize that LPI plus
LPIP would be more efficacious in opening up the angle
closure caused by multiple mechanisms and would pro-
vide greater intraocular pressure (IOP) control. It was
found in our previous randomized controlled trial that
LPI plus LPIP resulted in superior reduction in the PAS
surface area than LPI alone in synechial PAC and PACG
after 1-year follow-up, although a similar magnitude of
IOP reduction was reported for the two interventions
[13]. However, to our knowledge, a guideline has not
been published, nor have any studies been conducted,
on the treatment of PAC based on the clinical research
associate classification of various mechanisms of angle
closure.
Methods
Study objective
The aim of this study is to demonstrate the efficacy of
LPI plus LPIP versus LPI in reducing the rate of 3-year
disease progression in patients with multiple mecha-
nisms of angle closure based on UBM classification. A
secondary objective is to assess the safety of LPI plus
LPIP in the study population over its duration.
Trial design
This study has been designed as a 3-year, multicenter,
randomized, parallel group, open-label, superiority trial.
Interim analysis will not take place during this study. A
completed Standard Protocol Items: Recommendations
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for Interventional Trials (SPIRIT) checklist for the trial
is available (see Additional file 1).
Participant characteristics
Patients from the ten ophthalmic centers in China will
be assessed for suitability regarding participation in the
study by the primary investigator at each center and by
the researchers who confirm the UBM reading results,
using the criteria detailed herein.
Inclusion criteria
Inclusion criteria are as follows:
 Patients with a clinical diagnosis of PAC, with
IOP ≤ 30 mmHg and PAS ≤ 270 °.
 Patients with PAC with multiple mechanisms based
on the results of a UBM examination. (“Multiple
mechanisms” is defined as PAC caused by pupillary
block plus at least one non-pupillary block
mechanism).
 Patients with visual acuity ≥ 20/40.
 Patients who are aged 40–75 years and of Chinese
descent.
If both eyes of the patient are eligible for inclusion in
the study, the one with greater diminished visual acuity
will be selected. Only one eye per patient will be eligible
for inclusion in the study.
Eligible patients who are already on antiglaucoma
medication will be required to undergo a polypharmacy
washout before the randomization process is applied.
Different washout periods apply to the various medica-
tions, for example, prostaglandin analogs are eliminated
after 4 weeks, beta blockers after 3 weeks, adrenergic
agonists after 2 weeks, and cholinergic agonists and car-
bonic anhydrase inhibitors after 5 days. The polyphar-
macy washout process will be stopped in patients with
an IOP > 30 mmHg during the washout period and they
will be withdrawn from the study.
A diagnosis of PAC will be based on the 2010 Glau-
coma Preferred Practice Pattern® of eyes that are classi-
fied as having at least 180 ° of iridotrabecular contact
and an elevated IOP (IOP ≥ 21 mmHg) on at least one
occasion, with this result recurring three times, or PAS.
Visual field loss and glaucomatous optic neuropathy, as
defined herein, are exclusion criteria.
Exclusion criteria
The exclusion criteria are as follows:
 Patients who are unwilling or unable to provide
consent to participation in the study, who are
unwilling to submit to the randomization process, or
are unable to return for the scheduled protocol visits.
 Patients with angle closure due to secondary causes
(i.e., subluxated lens, neovascular, uveitic, traumatic
and postoperative).
 Patients who have undergone previous incisional
intraocular surgery or ocular laser in the study eye (LPI,
LPIP, cyclodestructive procedure, and cataract surgery).
 Patients with PAC with glaucomatous neuropathy.
 Patients who have a cataract in the study eye and who
anticipate having cataract surgery in the next 3 years.
(The existing cataract could affect the visual field and
fundus examination and it is likely that visual acuity
would be < 20/40 due to the existing cataract).
 Patients using IOP-lowing drugs who do not agree
to submit to the medication washout process.
 Patients who require glaucoma surgery combined
with other ocular procedures, such as cataract
surgery, penetrating keratoplasty, and retinal
surgery), or who anticipate the need for urgent
additional ocular surgery.
 Patients with other coexisting ocular diseases, such
as an abnormal cornea or a corneal infection,
iridocorneal endothelial syndrome, anterior segment
dysgenesis, nanophthalmos, high myopia (>6.0 D),
chronic or recurrent uveitis, ocular cancer, trauma,
central retinal vein occlusion, central retinal artery
occlusion, and retinal detachment).
 Patients with a corneal endothelium count of <
1000/mm2.
 Patients who require the long-term use of local or
systemic steroids.
 Patients who are unwilling to discontinue contact
lens use after surgery.
 Patients who are participating in other clinical trials.
 Pregnant or nursing women.
 Patients with severe systemic disease, such as diabetes
mellitus, hypertension, end-stage cardiac disease,
nephropathy, respiratory disease, and cancer.
 Patients who are allergic to pilocarpine or alcaine.
 Patients with a contraindication to laser treatment
for ocular disease.
Recruitment procedure
The participant flow diagram is showed in Fig. 1.
Sample size
The sample size calculations are based on published
PAC disease progression with LPI and LPIP treatment.
Disease progression is defined as glaucomatous optic
nerve injury, increased IOP for which antiglaucoma
drugs are required, and PAS progression according to
the published clinical trials [13–15]. It is assumed that
the 3-year PAC progression rate after receiving LPI will
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be approximately 55%, and the rate for LPI plus LPIP
will be 35%, with 80% statistical power and a two-sided
test at 5% significance. Thus, allowing for 20% loss to
follow-up, a sample size of 240 participants for this
study is required (calculated using nQuery Advisor® +
nTerim® 3.0 software; Statsols, Boston, MA, USA). There
will be 120 patients in each treatment arm. The antici-
pated number of patients in the study (240) will be re-
cruited over a 12-month period.
Randomization process
Patients will be randomly assigned to treatment with ei-
ther single LPI or LPI plus LPIP using a 1:1 ratio via an
online central randomization system. (This system is run
by personnel in the Department of Biostatistics, South-
ern Medical University, Guangzhou, China), using the
IOP as the stratification parameter. Patients will be
stratified into a high IOP subgroup (21 mmHg to ≤ 30
mmHg) and a low IOP subgroup (≤21 mmHg) since it is
likely that IOP will vary in the enrolled PAC partici-
pants. This procedure will ensure that there is a nearly
equal number of patients in each treatment group early
on in the trial and that the investigator will not be able
to predict the next treatment assignment. In addition,
the number of patients in the high and low IOP arms
will almost be equal. The intervention date is the study
entry date. Dates for all postoperative follow-up visits
will be computed from this date.
Blinding
This study is an open-label trial.
The classification of ultrasound biomicroscopy-based
angle closure
Patients who have been diagnosed with PAC will be
invited to undergo a UBM examination (SW3200L®;
Suowei Electronic Company, Tianjin, China). The UBM
examination will be conducted at every center by a tech-
nician with at least 3 years’ experience in operating a
UBM machine and who has also received training ac-
cording to the standard operating procedures of the
study. The UBM examination will be performed in a
dark room with illumination of ≤ 5 Lux. Images of the
four quadrants (the superior, inferior, nasal, and tem-
poral quadrants) and one image of the central anterior
chamber will be acquired in supine subjects.
The criteria for acceptable images will be clear
visualization of the scleral spur, angle, ciliary body, and
the half chord of the iris. After obtaining the UBM re-
sults, the research physicians will upload the UBM im-
ages (containing anonymized information) to an online
computer system that is only accessible to the UBM ana-
lysts, who will send the classification results on to the
research physician after reviewing the images and deter-
mining the results according to the UBM classification
criteria. The UBM analysts will consist of three glau-
coma specialists. Every UBM figure will be read by at
least two specialists. If agreement on the results cannot
be reached by the two specialists, a third will be
approached in order to obtain consensus.
The UBM classification criteria are as follows [5, 16]:
 Iris convexity: judged according to the curvature of
the posterior surface of the iris, the iris bombe is
defined as the location of the posterior surface of
the iris above a line drawn from the iris root to the
iris margin of the pupil (Fig. 2a).
 Thickness of the peripheral iris: the thickness of the
peripheral iris will be graded with reference to limbal
corneal thickness and is defined as greater than half the
thickness of the limbal zone of the cornea (Fig. 2b).
 Anterior rotation of the ciliary body: the anterior
rotation of the ciliary body will be judged according
to the direction of the axis of the ciliary body in the
anterior position, with the disappearance of the
ciliary groove (Fig. 2c).
Thus, there will be seven configurations (combina-
tions) of angle closure, as defined according to the afore-
mentioned criteria, including:
 The iris bombe.
Fig. 1 Participant flow diagram. LPI laser peripheral iridotomy, LPIP
laser peripheral iridoplasty, PAC primary angle closure
Chen et al. Trials  (2017) 18:130 Page 4 of 8
 Thickening of the peripheral iris.
 The anterior rotation of the ciliary body.
 The iris bombe plus thickening of the peripheral iris.
 The iris bombe plus the anterior rotation of the
ciliary body.
 Thickening of the peripheral iris plus the anterior
rotation of the ciliary body.
 The iris bombe plus thickening of the peripheral iris,
plus the anterior rotation of the ciliary body.
Multiple mechanisms of angle closure are defined as
combinations of two or three factors including the iris
bombe, thickening of the peripheral iris, and the anterior
rotation of the ciliary body.
Regarding the quadrants, the configuration of angle
closure in one eye is defined as at least two quadrants
belonging to one configuration; if two quadrants belong
to one kind of configuration, and the other two belong
to another kind of configuration, thereafter, reference
will be made to the contralateral eyes.
Intervention description
Single laser peripheral iridotomy
LPI will be performed using a VISULAS® 532 s diode
laser (Carl Zeiss Meditec, Dublin, USA). Thirty minutes
prior to the procedure, a drop of 2% pilocarpine will be
instilled into the eye every 15 minutes. Topical
anesthesia will be administered. The selected treatment
site will be the superior nasal iris or iris crypt, where
present. Treatment will be initiated with a pulse of 3–5
mJ. The power will be increased until patency is
achieved and the opening of the iris is > 0.1 mm. Patency
will be determined by direct visualization of the poster-
ior chamber.
Laser peripheral iridoplasty plus laser peripheral iridotomy
LPIP will be applied using a VISULAS® 532 s diode laser
(Carl Zeiss Meditec). Thirty minutes prior to the proced-
ure, a drop of 2% pilocarpine will be instilled into the
eye every 15 minutes, Topical anesthesia will be admin-
istered. Twenty to 30 ms spots of 250–300 mW power,
measuring 300–500 microns, will be applied for a dur-
ation of 400–500 ms. Power will be modified arbitrarily
until an effective iris contraction is obtained. Effective
iris contraction will be considered to constitute concen-
tric movement around the laser spot, with minimal iris
pigmentation and immediate angle opening, as observed
through a Goldmann® lens mirror. Power will be lowered
if a bursting sound is perceived, or in the event of pig-
ment dispersion, air bubbles, or considerable pain. LPI
will be performed after the LPIP procedure is complete.
Primary outcome measures
The PAC progression rate will be determined by the
number of patients in whom the disease progresses fol-
lowing laser treatment in each group within the 3-year
follow-up period. PAC progression is defined as the
presence of any of the following:
 Acute angle-closure crisis.
 An IOP measurement taken 1 month after the laser
procedure that is 8 mmHg higher than that
recorded at treatment initiation.
 An IOP measurement taken 1 month after the laser
procedure that is ≥ 22 mmHg when measured three
times in succession.
 The progression of PAS ≥ 1 clock hour within 3 years
of the laser procedure, as determined by gonioscopy.
 Glaucomatous neuropathy within 3 years of the
laser procedure.
Acute angle-closure crisis is defined as:
 The presence of at least two of the following
symptoms: ocular or periocular pain, nausea and
vomiting, blurred vision, and multicolored halos
around lights (an occasional symptom).
 An IOP measurement of at least 22 mmHg, as
measured by Goldmann® applanation tonometry.
 The presence of at least three of the following signs:
conjunctival injection, corneal edema, a mid-dilated
unreactive pupil, and a shallow anterior chamber.
Fig. 2 UBM-based angle closure configuration classification. a Thickening of the peripheral iris; b iris bombe; c anterior rotation of the ciliary
body. UBM ultrasound biomicroscopy
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Glaucomatous neuropathy is defined as:
 The documented progression of diffuse thinning and
focal narrowing or notching of the optic disc rim.
 A cup disc ratio of ≥ 0.6.
 A cup-disc asymmetry ratio of ≥ 0.2 for similar-sized
eyes or optical discs.
 Diffuse or localized abnormalities in the
peripapillary retinal nerve fiber layer.
 The presence of glaucomatous visual field defect,
defined as reproducible visual field defects, including
nasal step, arcuate field defect, or paracentral
depression in the clusters of the test sites.
 Visual field loss in the upper hemifield that is
different to that in the lower hemifield.
 The absence of any other known explanation.
Secondary outcome measures
Secondary outcome measures include the following:
 Determining, through the administration of a
questionnaire, whether or not additional medication
(to control IOP) or additional surgery is required to
control the progression of PAC.
 Establishing whether or not there are any changes in
the best-corrected visual acuity after the laser
procedure.
 Determining the number of corneal endothelium cells.
 Establishing any change in the angle width and
configuration, as measured by UBM.
Safety evaluation
An evaluation of the safety of the procedures, including
any laser-related complications and adverse events, will
be conducted and will cover:
 Corneal injury: corneal injury will be sought via an
examination by slit lamp and by conducting a
corneal endothelium cell count.
 Anterior uveitis: inflammation in the anterior
chamber is indicative of anterior uveitis.
 Changes in the pupil: any changes to the pupil will
be established following an examination by slit lamp.
 Lens injury: lens injury will be determined following
an examination by slit lamp.
 Retinal injury: a fundus examination will be
conducted to evaluate whether or not retinal injury
has occurred.
 Blindness: blindness will constitute a major adverse
event.
Data collection and monitoring
All data will be collected at the scheduled follow-up
times (Table 1). Trained clinical research associates at
each center will examine the data on the patient informa-
tion sheet, all of which will be entered into a trial-specific
online database, Research Electronic Data Capture®. The
data manager will monitor the data in a timely manner to
control the quality of the data. Access to the final dataset
will be limited to the trial administrator and the
statistician.
Data analysis
The statistical tests will be two-sided. A level of 0.050
will constitute statistical significance. A comparison of
the normally distributed continuous variables between
two groups, expressed as mean ± standard deviation, will
be determined using two independent t tests. The nat-
ural logarithmic transformation will be applied to vari-
ables that are positively skewed. Non-normally
distributed continuous variables, presented as the me-
dian and interquartile range, will be analyzed using the
Wilcoxon rank-sum test. The ordinary variables, also
presented as median and interquartile range or percent-
ages, will be analyzed using Wilcoxon signed-rank test.
Pearson’s chi-square test or Fisher’s exact test will be
used, as appropriate, for the categorical data and
expressed as percentages. If the primary outcome is not
realized, the last observation carried forward method
will be used to impute the reason why. Any other values
will remain as absent. The baseline characteristics will
be evaluated using intent-to-treat (ITT) analysis. Efficacy
analysis will be applied to the ITT and per protocol pop-
ulations. Reasons for loss to follow-up will also be
presented.
An evaluation of the rate of disease progression
after 3 years of follow-up will be conducted using
efficacy analysis as the primary outcome measure. A
comparison in this regard will be made between the
LPI and LPI plus LPIP groups using Pearson’s χ2 test.
Logistic regression analysis will be performed to
evaluate the central effect and the progression rate
adjusted to account for it.
The safety evaluation data, as per the secondary
outcome, will be analyzed using a generalized linear
model in consideration of any covariates or the
central effect. Sensitivity analysis will be conducted to
assess for heterogeneity. Statistical Analysis Software®
9.4 (SAS Institute Inc., Cary, NC, USA) will be used
to analyze the collected data. The data analysis will
be performed by personnel in the Department of
Biostatistics, Southern Medical University, Guangzhou,
China.
Discussion
LPI alone is not considered to be sufficient to treat the
large number of PAC patients with multiple mechanisms
of angle closure in China. Laser treatment, based on the
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type of angle closure, is reasonable and necessary. A
multicenter, prospective, randomized controlled trial on
the optimal laser treatment for PAC is mandatory but is
currently lacking. This trial is the first multicenter,
prospective, randomized controlled trial that will evalu-
ate the effect and safety of LPI plus LPIL, compared with
LPI alone, for the treatment of PAC with multiple
mechanisms based on UBM classification. The findings
are expected to provide evidence that laser treatment for
PAC should be based on the mechanism of angle
closure.
Strengths of this trial include the fact that UBM-based
angle-closure classification will be used, central
randomization will be applied, the IOP will be classified
as high and low, and the follow-up will be over a long
term (3 years).
It was found by Jiang et al. that a thick peripheral iris
was more relevant to a narrow angle configuration,
based on UBM images in Chinese patients, although the
anterior rotation of the ciliary body and the iris insertion
was similar to that in narrow- and wide-angle eyes.
However, on the other hand, it was demonstrated that
multiple mechanisms were involved in angle closure in
Chinese PAC patients [16].
Thus, the use of laser treatment (LPI plus LPIP), based
on the UBM classification in the current study, was pru-
dent. Though our previous randomized controlled trial
stated that the use of LPI plus PLPI achieved an equiva-
lent reduction in IOP in PAC and PACG, in that study
both PAC and PACG patients with PAS were included
and the type of angle closure was not classified, which
may have influenced the results [13].
The classification of angle closure, based on the UBM
images, is an issue that requires attention. Since there is
no unified guideline on the UBM classification of angle
closure, we referred to the previous hospital-based popu-
lation study and the Liwan Eye Study carried out at
Zhongshan Ophthalmic Center [5, 16]. Since UBM clas-
sification is semiquantitative, we used UBM analysts to
avoid possible bias.
Trial status
Recruitment for the MAC study began in November
2015. It is ongoing. Currently, more than 25% of the
sample size has been attained. Since the recruitment
rate is relatively slow, it is anticipated that the study
will reach the recruitment target of 240 participants by
June 2017.
Table 1 Schedule of visits and examination items
Visit number 1 2 3 4 5 6 7 8 9 10 11 12
Examination item -7 to
-1 day
Laser
day
1 W
(±1 D)
1 M
(±1 W)
3 M
(±1 W)
6 M
(±1 W)
1 Y
(±2 W)
1½ Y
(±2 W)
2 Y
(±2 W)
3 Y
(±2 W)
4 Y
(±2 W)
5 Y (±2 W)
EOS
Informed consent X
Demographics data X
Medical history X
Vital signs X X X
Height and weight X
Medication record X X X X X X X X X X X
Refraction Xb X X X X X X X Xb
Visual acuity Xb X X X X X X X X X Xb
Slit lamp biomicroscopy Xb X X X X X X X X X Xb
Fundus examination Xb X X X X X X X Xb
IOP (Goldmann) Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb
A scan Xb X X X X Xb
Endothelial cell count Xb X X X X X X Xb
UBM Xb X X X X X X X Xb
AS-OCT (Xb) (X) (X) (X) (X) (X) (X) (X) (Xb)
Humphrey 24-2 Xb X X X X X Xb
Antiglaucoma surgery X X X X X X X X X
Laser treatment X
Adverse event X X X X X X X X X X X X
Xb: examination item for both eyes; (x): optional examination item (AS-OCT)
EOS, the end of the study, IOP intraocular pressure, UBM ultrasound biomicroscopy, AS-OCT anterior segment optical coherence tomography, W week, M month, Y year
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